Raab & Moskowitz Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Raab & Moskowitz Asset Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$234K	Hold	3,115	–	–	0.05%	179
2025 Q4	$246K	Hold	3,115	–	–	0.05%	177
2025 Q3	$204K	Buy	+3,115	New	+$152K	0.05%	184
2020 Q1	–	Sell	-3,221	Closed	-$194K	–	318
2019 Q4	$194K	Buy	+3,221	New	+$192K	0.08%	161
2019 Q3	–	Sell	-3,233	Closed	-$207K	–	159
2019 Q2	$207K	Hold	3,233	–	–	0.09%	152
2019 Q1	$262K	Buy	+3,233	New	+$209K	0.12%	136
2018 Q4	–	Sell	-3,233	Closed	-$166K	–	326
2018 Q3	$166K	Buy	+3,233	New	+$152K	0.07%	173

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raab & Moskowitz Asset Management's IONS Position: Q1 2026 in Review

Raab & Moskowitz Asset Management held its Ionis Pharmaceuticals (IONS) position steady in Q1 2026 at 3,115 shares worth $234K. The position accounts for 0.05% of the portfolio, ranked #179.

Raab & Moskowitz Asset Management first reported a position in IONS in Q3 2018 and has held it in 7 quarters since. The position peaked at $262K in Q1 2019. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

Raab & Moskowitz Asset Management held 3,115 shares of Ionis Pharmaceuticals worth $234K as of Q1 2026.
Raab & Moskowitz Asset Management left its Ionis Pharmaceuticals share count unchanged in Q1 2026.
Ionis Pharmaceuticals made up 0.05% of Raab & Moskowitz Asset Management's portfolio in Q1 2026, its #179 holding.
Raab & Moskowitz Asset Management first reported a position in Ionis Pharmaceuticals in Q3 2018 and has held it in 7 quarters since.
Raab & Moskowitz Asset Management's Ionis Pharmaceuticals position peaked at $262K in Q1 2019.
493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Raab & Moskowitz Asset Management's 13F filing for Q1 2026, filed 21 May 2026.